Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
The company expects to report topline data from the study in the summer of 2020.
Read MoreSelect Page
Posted by Invest In Weed | Nov 18, 2019
The company expects to report topline data from the study in the summer of 2020.
Read MorePosted by Invest In Weed | Nov 14, 2019
The planned acquisition has the potential to accelerate its 505(b)(2) drug pipeline and expedite its growth with a planned 2020 launch of Consensi.
Read MorePosted by Invest In Weed | Nov 11, 2019
Median ACR CRISS score remains 0.95 at 25 months in systemic sclerosis OLE.
Read MorePosted by Invest In Weed | Nov 11, 2019
51.9% of patients in the difelikefalin group achieved the pre-specified primary outcome.
Read MorePosted by Invest In Weed | Nov 10, 2019
Cannabidiol oral solution is recommended as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome.
Read MoreGet stock alerts, news & related alerts straight to your inbox!